Skip to main content
Premium Trial:

Request an Annual Quote

Nanogen Licenses Gene Variants from Pathway Diagnostics for Dx Predicting Drug Response

NEW YORK, March 22 (GenomeWeb News) - Nanogen has licensed genetic variations from Pathways Diagnostics that predict patients' response to antidepressants and antipsychotic in order to create a diagnostic product, the company said today.

 

Under the non-exclusive agreement, the companies have been working on a molecular diagnostic product, based on Nanogen's NanoChip platform, to determine the appropriate drug dosage for patients with psychiatric disorders. Nanogen plans to include Pathways' gene variations along with cytochrome P450 family members.

 

The companies did not disclose financial details of the agreement.

The Scan

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.

Study Reviews Family, Provider Responses to Rapid Whole-Genome Sequencing Follow-up

Investigators identified in the European Journal of Human Genetics variable follow-up practices after rapid whole-genome sequencing.

BMI-Related Variants Show Age-Related Stability in UK Biobank Participants

Researchers followed body mass index variant stability with genomic structural equation modeling and genome-wide association studies of 40- to 72-year olds in PLOS Genetics.

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.